康恩贝：子公司盐酸丙卡特罗吸入溶液获得药品注册证书

Core Viewpoint - The company has received approval from the National Medical Products Administration for two specifications of the drug, Salbutamol Hydrochloride Inhalation Solution, which is primarily used to alleviate symptoms of bronchial asthma, chronic bronchitis, and emphysema [1] Group 1 - The company's wholly-owned subsidiary, Zhejiang Jinhua Kang En Bei Biopharmaceutical Co., Ltd., has been granted a drug registration certificate for Salbutamol Hydrochloride Inhalation Solution [1] - The drug is indicated for diseases characterized by airflow limitation, including bronchial asthma, chronic bronchitis, and emphysema [1] - The company has invested approximately 6.85 million RMB in the research and development of Salbutamol Hydrochloride Inhalation Solution to date [1]